Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

Health ProfessionalsPatients

No longer recruiting (closed or complete)Last updated: 6 November 2025

ALLG-PACIFIC: This study is evaluating whether combining immunotherapy with chemotherapy will improve outcomes for people with primary mediastinal B-cell lymphomaNHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL).

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People18+

Trial acronym

ALLG-PACIFIC

Clinical summary

Summary

This study is testing whether adding immunotherapy (called pembrolizumab) to R-CHOP chemotherapy (consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) improves survival of patients with primary mediastinal B-cell lymphoma.

All participants will receive the following treatment. All treatment cycles are 21 days.

Cycles 1 and 2: R-pembro 'window': rituximab 375mg/m2 Intravenous infusion (IV) on Day 1 + pembrolizumab 200mg via IV on Day 1.

Cycles 3-8 'Induction': rituximab 375mg/m2 via IV on Day 1, cyclophosphamide 750mg/m2 via IV on Day 1, doxorubicin 50mg/m2 via IV on Day 1, vincristine 1.4mg/m2 via IV on Day 1 capped at 2mg, prednisolone 100mg oral tablet on Days 1-5, and pembrolizumab 200mg via IV on Day 1.

Cycles 9-17 pembrolizumab 'consolidation': pembrolizumab 200mg via IV on Day 1.

Participants will have a PET/CT Scan at the following timepoints: after registration, after the 'pembro' phase, and after the 'induction' phase. Participants may have another PET/CT Scan at the discretion of their treating physician. Patients will also have blood samples taken every three weeks whilst receiving treatment.

Conditions

This trial is treating people with primary mediastinal B-Cell lymphoma

Eligibility

Inclusion

1. Subjects aged equal to greater than 18 years at time of enrolment.
2. Able to give informed consent.
3. Clinical and histological diagnosis of PMBL, according to the current World Health Organization classification.
4. No previous treatment for lymphoma including chemotherapy, radiotherapy or other investigational drug.
5. Eastern Collaborative Oncology Group performance status 0-<=1.
6. Platelets >= 100x109/l; neutrophils >= 1.0x109/l at the time of study entry.
7. Creatinine clearance >=30ml/min (calculated according to MRDR or Cockcroft Gault equation)
8. Total bilirubin less than or equal to 1.5 × ULN, AST and ALT less or equal to 2..5 x ULN
9. LVEF greater or equal to 45%

Exclusion

1. Known hypersensitivity to any study medication, including previous grade >=3 hypersensitivity reactions to monoclonal antibody therapy.
2. Active autoimmune disease; requiring immunosuppressive therapy within 6 months of study entry.
3. Other lymphoma subtypes, other than PMBL.
4. Central nervous system, meningeal or spinal cord involvement by lymphoma.
5. Prior therapy with any antibody or drug targeting T-cell coregulatory proteins (immune checkpoints) such as PD-1, PD-L1, or cytotoxic T-lymphocyte antigen-4 (CTLA-4).
6. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. – Please note that a short course of steroids (e.g. Oral Prednisolone 1mg/kg daily or equivalent for <=7 days duration) will be permitted if indicated for lymphoma symptoms (but should be avoided if possible)

Inclusion

  • You have been diagnosed with cancer, but have not received any treatment.
  • You are able to swallow medication by mouth.

Exclusion

  • You are currently being treated on a clinical trial.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

Australasian Leukaemia and Lymphoma Group (ALLG)

Scientific Title

NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL).

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait